

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CROCKER GARY L</u> _____ (Last) (First) (Middle) <u>C/O MERRIMACK PHARMACEUTICALS, INC.</u> <u>ONE BROADWAY 14TH FLOOR</u> _____ (Street) <u>CAMBRIDGE MA 02142</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MERRIMACK PHARMACEUTICALS INC [ MACK ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/22/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/22/2020		S		17,000	D <sup>(6)(7)</sup>	\$3.202	0	D <sup>(1)</sup>	
Common Stock	07/22/2020		S		5,986	D <sup>(6)(7)</sup>	\$3.0419	0	D <sup>(1)</sup>	
Common Stock	07/22/2020		S		8,428	D <sup>(6)(7)</sup>	\$3.202	0	D <sup>(2)</sup>	
Common Stock	07/22/2020		S		86,549	D <sup>(6)(7)</sup>	\$3.0419	0	D <sup>(2)</sup>	
Common Stock	07/22/2020		S		52,068	D <sup>(6)(7)</sup>	\$3.0419	0	I	See Footnote <sup>(3)</sup>
Common Stock	07/22/2020		S		17,250	D <sup>(6)(7)</sup>	\$3.202	0	I	See Footnote <sup>(4)</sup>
Common Stock	07/22/2020		S		6,228	D <sup>(6)(7)</sup>	\$3.202	0	I	See Footnote <sup>(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- Shares held directly by Reporting Person.
- Shares held jointly with Reporting Person's wife.
- Shares held directly by Reporting Person's wife.
- Shares held by Crocker Family Investments, LLC, over which Reporting Person is the Managing Member.
- Shares held by Crocker Ventures, LLC, over which Reporting Person is the President and Managing Member.
- The sale of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers, regarding all shares of the Company over which he had dispositive control, along with the record owners of most of the shares of the Company over which Reporting Person had voting control. The purpose of the sale was to minimize tax liability by matching losses from these sales of Company stock with other investment gains. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P.
- (continued from footnote 6) Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP.

**Remarks:**

In addition to the sale of securities referenced in Table I of this Form 4, 161,039 shares held by certain trusts established for members of Reporting Person's family, certain entities controlled by members of his family and certain individual members of his family, and in which Reporting Person has no pecuniary interest, were also sold to the purchasers (111,453 shares at a price of \$3.2020 per share, and 49,586 shares at a price of \$3.0419 per share). Such holders were parties to a Shareholder Voting Agreement dated December 20, 2010, pursuant to which the parties to the agreement had agreed to vote his, her or its shares as directed by Crocker Ventures, LLC. Reporting Person is the President and Managing Member of Crocker Ventures, LLC and in connection therewith shared voting control over all the shares subject to the Shareholder Voting Agreement. In connection with the disposition of shares disclosed herein, the Shareholder Voting Agreement has been terminated and thus the Reporting Person no longer shares voting control of any shares held by third parties.

/s/ Gary L. Crocker 07/24/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**